Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Capital Expenditures (2016 - 2025)

Rockwell Medical's Capital Expenditures history spans 16 years, with the latest figure at $86000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 78.23% year-over-year to $86000.0; the TTM value through Dec 2025 reached $542000.0, down 46.39%, while the annual FY2025 figure was $542000.0, 46.39% down from the prior year.
  • Capital Expenditures reached $86000.0 in Q4 2025 per RMTI's latest filing, down from $229000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $395000.0 in Q4 2024 to a low of -$80000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $132000.0, with a median of $120500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: crashed 162.99% in 2022, then skyrocketed 1093.75% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $114000.0 in 2021, then skyrocketed by 146.49% to $281000.0 in 2022, then plummeted by 84.7% to $43000.0 in 2023, then surged by 818.6% to $395000.0 in 2024, then plummeted by 78.23% to $86000.0 in 2025.
  • Per Business Quant, the three most recent readings for RMTI's Capital Expenditures are $86000.0 (Q4 2025), $229000.0 (Q3 2025), and $164000.0 (Q2 2025).